Medicare Enrolled
Dr. Adewale Fawole, M.D.
Hematology · The Villages, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Fawole from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Fawole? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Fawole
Dr. Adewale Fawole is a hematology in The Villages, FL, with 16 years in practice. Based on federal Medicare data, Dr. Fawole performed 155,235 Medicare services across 5,230 unique beneficiaries.
Between the years covered by Open Payments, Dr. Fawole received a total of $10,873 from 67 pharmaceutical and/or device companies across 524 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Fawole is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 16 years in practice▲ Top 34% volume in FL$ $10,873 industry payments
Medicare Practice Summary
Medicare Utilization ↗155,235
Medicare services
Top 34% in FL for hematology
5,230
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~9,702 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 30,600 | $0 | $4 |
| Filgrastim injection (Zarxio) for white blood cells | 20,940 | $0 | $2 |
| Iron infusion (Injectafer) | 18,750 | $1 | $3 |
| Anti-nausea injection (aprepitant) | 16,900 | $1 | $5 |
| Pembrolizumab injection (Keytruda) | 15,800 | $43 | $137 |
| Iron infusion (Monoferric) | 8,800 | $17 | $57 |
| Denosumab injection (Prolia/Xgeva) | 8,640 | $18 | $51 |
| Paclitaxel chemotherapy injection | 5,724 | $0 | $2 |
| Iron sucrose injection (Venofer) | 5,200 | $0 | $5 |
| Dexamethasone injection (steroid) | 2,974 | $0 | $3 |
| Injection, eflapegrastim-xnst, 0.1 mg | 2,904 | $26 | $116 |
| Complete blood count (CBC) with differential | 2,423 | $8 | $29 |
| Blood draw (venipuncture) | 2,260 | $8 | $9 |
| Epoetin alfa injection (Procrit) for anemia | 2,160 | $6 | $23 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,800 | $1 | $28 |
| Office visit, established patient (30-39 min) | 1,151 | $95 | $339 |
| Anti-nausea injection (ondansetron/Zofran) | 824 | $0 | $9 |
| Drug injection, under skin or into muscle | 746 | $10 | $69 |
| Administration of chemotherapy into vein, 1 hour or less | 606 | $97 | $378 |
| Injection, fluorouracil, 500 mg | 571 | $2 | $7 |
| Injection of additional new drug or substance into vein | 538 | $12 | $61 |
| Injection, leucovorin calcium, per 50 mg | 466 | $3 | $12 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 382 | $47 | $189 |
| Injection, zoledronic acid, 1 mg | 354 | $6 | $69 |
| Office visit, established patient (20-29 min) | 316 | $62 | $239 |
| Injection, cisplatin, powder or solution, 10 mg | 268 | $2 | $13 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 259 | $1 | $6 |
| Injection, carboplatin, 50 mg | 240 | $2 | $41 |
| Administration of chemotherapy into vein, each additional hour | 219 | $21 | $79 |
| Infusion into a vein for hydration, each additional hour | 205 | $10 | $42 |
| New patient office visit (45-59 min) | 202 | $121 | $453 |
| Administration of additional new drug or substance into vein, 1 hour or less | 175 | $49 | $178 |
| Initial hospital admission, high complexity | 150 | $137 | $556 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 137 | $21 | $84 |
| Injection, magnesium sulfate, per 500 mg | 126 | $1 | $2 |
| Injection, diphenhydramine hcl, up to 50 mg | 119 | $1 | $3 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 110 | $54 | $206 |
| Injection of drug or substance into vein | 90 | $27 | $156 |
| Infusion, normal saline solution , 1000 cc | 88 | $2 | $7 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 87 | $134 | $562 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 86 | $15 | $56 |
| Hospital follow-up visit, moderate complexity | 86 | $63 | $197 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 84 | $17 | $59 |
| Administration of additional new drug or substance into vein using push technique | 83 | $42 | $170 |
| Automated urinalysis | 71 | $2 | $8 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 62 | $123 | $637 |
| Prothrombin time test (blood clotting) | 60 | $4 | $15 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 52 | $24 | $89 |
| Office visit, established patient, complex (40-54 min) | 52 | $133 | $474 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 44 | $1 | $7 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 40 | $3 | $11 |
| Red blood count, automated test | 38 | $4 | $10 |
| Infusion into a vein for hydration, 31-60 minutes | 34 | $25 | $156 |
| Red blood count automated, with additional calculations | 30 | $5 | $20 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 30 | $15 | $56 |
| Drawing of blood for a medical problem | 22 | $63 | $277 |
| Hospital follow-up visit, high complexity | 22 | $94 | $285 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 18 | $135 | $467 |
| Unclassified biologics | 17 | $3,634 | $15,280 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
38.1% high complexity
57.1% medium
4.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$10,873
Total received (2018-2024)
Avg $1,553/year across 7 years
Top 40% in FL for hematology
67
Companies
524
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$10,473 (96.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$400 (3.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$3,182
2023$2,438
2022$2,437
2021$1,917
2020$528
2019$253
2018$117
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Celgene Corporation
$1,113
Janssen Biotech, Inc.
$831
Novartis Pharmaceuticals Corporation
$756
PFIZER INC.
$705
AstraZeneca Pharmaceuticals LP
$563
Amgen Inc.
$379
E.R. Squibb & Sons, L.L.C.
$370
Seagen Inc.
$337
ABBVIE INC.
$328
Merck Sharp & Dohme LLC
$323
Incyte Corporation
$281
GENZYME CORPORATION
$279
Blueprint Medicines Corporation
$270
Kite Pharma, Inc.
$266
Daiichi Sankyo Inc.
$256
GlaxoSmithKline, LLC.
$251
Eisai Inc.
$246
BeiGene USA, Inc.
$230
Pharmacyclics LLC, An AbbVie Company
$201
Astellas Pharma US Inc
$197
Lilly USA, LLC
$186
Genentech USA, Inc.
$175
Alexion Pharmaceuticals, Inc.
$171
ARRAY BIOPHARMA INC
$160
JAZZ PHARMACEUTICALS INC.
$156
EISAI INC.
$135
Gilead Sciences, Inc.
$119
Boehringer Ingelheim Pharmaceuticals, Inc.
$113
G1 Therapeutics, Inc.
$90
TerSera Therapeutics LLC
$89
MorphoSys, US Inc.
$87
Takeda Pharmaceuticals U.S.A., Inc.
$86
Foundation Medicine, Inc.
$86
Pharmacosmos Therapeutics Inc.
$84
Adaptive Biotechnologies Corporation
$63
EMD Serono, Inc.
$53
Karyopharm Therapeutics Inc.
$51
Regeneron Healthcare Solutions, Inc.
$43
SOBI, INC
$43
PUMA BIOTECHNOLOGY, INC.
$42
SUN PHARMACEUTICAL INDUSTRIES INC.
$41
Mirati Therapeutics, Inc.
$40
Tempus AI, Inc
$39
Stemline Therapeutics Inc.
$37
CTI BioPharma Corp.
$36
SERVIER PHARMACEUTICALS LLC
$34
Bayer HealthCare Pharmaceuticals Inc.
$33
Global Blood Therapeutics, Inc.
$30
Kyowa Kirin, Inc.
$28
Sobi, Inc
$25
PharmaEssentia USA Corporation
$25
ImmunoGen, Inc.
$24
Myovant Sciences Inc.
$23
Exelixis Inc.
$23
Telix Pharmaceuticals
$23
EUSA Pharma (US) LLC
$20
AbbVie Inc.
$20
Dova Pharmaceuticals
$19
TOLMAR Pharmaceuticals, Inc.
$19
Bayer Healthcare Pharmaceuticals Inc.
$18
Epizyme, Inc.,
$17
Rigel Pharmaceuticals, Inc.
$17
Servier Pharmaceuticals LLC
$15
Merck Sharp & Dohme Corporation
$15
Ipsen Biopharmaceuticals, Inc
$14
AMAG Pharmaceuticals, Inc.
$13
SECURA BIO, INC.
$11
Top 3 companies account for 24.8% of total payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · ALUNBRIG · AUGTYRO · AYVAKIT · Alecensa · BAVENCIO · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · COPIKTRA · COSELA · CYRAMZA · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIGARD · ELIQUIS · ELITEK · ELREXFIO · ENHERTU · EPKINLY · ERLEADA · Enhertu · FERAHEME · FOUNDATIONONE · FRUZAQLA · GAVRETO · GILOTRIF · IBRANCE · ICLUSIG · ILLUCCIX · IMBRUVICA · IMFINZI · INFLECTRA · INLYTA · Imbruvica · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MONOFERRIC · NERLYNX · Nplate · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Odomzo · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · Padcev · Polivy · Pomalyst · Poteligeo · Quzyttir · REBLOZYL · RYBREVANT · SARCLISA · SCEMBLIX · SHINGRIX · SOMATULINE DEPOT · Soliris · Stivarga · Sylvant · TABRECTA · TAGRISSO · TASIGNA · TAZVERIK · TEVIMBRA · TIBSOVO · TIVDAK · TUKYSA · Tavalisse · Tecentriq · Tibsovo · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · Venclexta · Vonjo · WELIREG · XALKORI · XGEVA · XOSPATA · XPOVIO · XT CDX · XTANDI · Xospata · Xtandi · Yescarta · ZEJULA · ZEPZELCA · Zoladex · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $7 per 100 Medicare services performed
Geographic Context
Hematologys within 10 mi
11
Per 100K population
8.0
County median income
$73,297
Nearest hospital
UF HEALTH LEESBURG HOSPITAL
6.4 mi
6.4 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Fawole is a mixed practice specialist, with moderate Medicare volume, and low-engagement industry engagement, with 16 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Fawole experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Fawole performed 30,600 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Fawole receive payments from pharmaceutical companies?
Yes. Dr. Fawole received a total of $10,873 from 67 companies across 524 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Fawole's costs compare to other hematologys in The Villages?
Dr. Fawole's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Fawole) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologys in The Villages
Browse hematologys in The Villages ranked by procedure volume and transparency data.
Highest volume
Top Hematologys in FL
Hematologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologys in FL
Which FL hematologys receive the most from drug and device companies.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology